Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease | Scientific Reports
Kawasaki disease: pathophysiology and insights from mouse models | Nature Reviews Rheumatology
Kawasaki Disease: Practice Essentials, Background, Pathophysiology
Combination therapy reduces risk for abnormalities, treatment failure in Kawasaki disease
Mortality among Children with Kawasaki Disease in Japan | NEJM
Late Treatment and Recurrence of Kawasaki Disease in a Moroccan Infant
Mortality among Children with Kawasaki Disease in Japan | NEJM
Frontiers | Epidemiology of Kawasaki Disease in Europe
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease | Circulation
Refractory Kawasaki disease - UpToDate
Clinical Practice Guidelines : Kawasaki disease
The up‐to‐date pathophysiology of Kawasaki disease - Hara - 2021 - Clinical & Translational Immunology - Wiley Online Library
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a
Frontiers | Thirty Years of Kawasaki Disease: A Single-Center Study at the University Hospital of Lausanne
Environmental epidemiology of Kawasaki disease: Linking disease etiology, pathogenesis and global distribution | PLOS ONE
Kawasaki disease in children: Epidemiology, clinical symptoms and diagnostics of 231 cases in 10 years
Kawasaki disease: insights into pathogenesis and approaches to treatment | Nature Reviews Rheumatology
Abstract 134: Early Immunoglogulin Therapy and Outcomes of Kawasaki Disease | Circulation
Kawasaki disease recurrence in the COVID-19 era: a systematic review of the literature | Italian Journal of Pediatrics | Full Text
Children | Free Full-Text | Major Complication Following Kawasaki Disease in an Infant—The Development of Apical Infarction and Aneurysm Formation
Medicina | Free Full-Text | Clinical Manifestations of Kawasaki Disease at Different Age Spectrum: A Ten-Year Study
Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study | Journal of the American Heart Association
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association | Circulation
Rheumato | Free Full-Text | Kawasaki Disease: Management Challenges during COVID-19 Pandemic with an Upsurge in Multisystem Inflammatory Syndrome in Children
Clinical characteristics of patients with recurrent Kawasaki disease: a nationwide cohort study of 19 456 patients with minimum 3-year follow up | Archives of Disease in Childhood
Recurrent Kawasaki disease presenting as acute airway obstruction
